Janssen-Cilag International NV, a subsidiary of Johnson & Johnson (JNJ), has revealed new findings from the Phase 1b/2 OrigAMI-1 study. The data indicates that amivantamab, when combined with chemotherapy (either mFOLFOX6 [FOLFOX] or FOLFIRI), exhibits promising rapid and durable anti-tumor activity in patients with RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC) who have not previously received anti-epidermal growth factor receptor (EGFR) therapy.The study highlighted that patients receiving the combination of amivantamab and chemotherapy achieved an overall response rate (ORR) of 49%, with a median duration of response of 7.4 months, and a median progression-free survival of 7.5 months. Additionally, disease control was achieved in 88% of participants. Noteworthy intrahepatic anti-tumor activity was evident among patients with liver metastases, marked by a significant reduction in liver tumors (with an ORR of 53% and a disease control rate of 93%). Importantly, nine patients (21%) were able to undergo curative intent surgery due to the robust anti-tumor response.Colorectal cancer ranks as the third most prevalent cancer globally and the second most common cancer in Europe, with over 538,000 new cases diagnosed in 2022.The material has been provided by InstaForex Company – www.instaforex.com
- France’s HICP Growth Slightly Eases in September: A Year-Over-Year Analysis - October 15, 2024
- France’s Harmonized Consumer Prices Index Dips in September 2024, Marking a Significant Economic Shift - October 15, 2024
- French Inflation Faces Sharp Decline in September: CPI Records -1.3% - October 15, 2024
